JP2019137675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019137675A5 JP2019137675A5 JP2019019212A JP2019019212A JP2019137675A5 JP 2019137675 A5 JP2019137675 A5 JP 2019137675A5 JP 2019019212 A JP2019019212 A JP 2019019212A JP 2019019212 A JP2019019212 A JP 2019019212A JP 2019137675 A5 JP2019137675 A5 JP 2019137675A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- conjugate according
- seq
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 68
- 102000007238 Transferrin Receptors Human genes 0.000 claims 16
- 108010033576 Transferrin Receptors Proteins 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 210000003205 muscle Anatomy 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 5
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 4
- 208000033868 Lysosomal disease Diseases 0.000 claims 4
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 208000024720 Fabry Disease Diseases 0.000 claims 3
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 3
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 201000004502 glycogen storage disease II Diseases 0.000 claims 3
- 230000002132 lysosomal effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000004220 muscle function Effects 0.000 claims 3
- 230000005996 muscular dysfunction Effects 0.000 claims 3
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 1
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 1
- 102000043404 human GLA Human genes 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023150649A JP7591340B2 (ja) | 2018-02-05 | 2023-09-19 | 薬剤を筋肉に送達するための方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018018652 | 2018-02-05 | ||
| JP2018018652 | 2018-02-05 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150649A Division JP7591340B2 (ja) | 2018-02-05 | 2023-09-19 | 薬剤を筋肉に送達するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019137675A JP2019137675A (ja) | 2019-08-22 |
| JP2019137675A5 true JP2019137675A5 (https=) | 2022-01-18 |
Family
ID=67479985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019212A Pending JP2019137675A (ja) | 2018-02-05 | 2019-02-05 | 薬剤を筋肉に送達するための方法 |
| JP2023150649A Active JP7591340B2 (ja) | 2018-02-05 | 2023-09-19 | 薬剤を筋肉に送達するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150649A Active JP7591340B2 (ja) | 2018-02-05 | 2023-09-19 | 薬剤を筋肉に送達するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210038739A1 (https=) |
| EP (1) | EP3750921A4 (https=) |
| JP (2) | JP2019137675A (https=) |
| KR (1) | KR20200116952A (https=) |
| CN (1) | CN111683972A (https=) |
| AU (1) | AU2019215782A1 (https=) |
| BR (1) | BR112020013305A2 (https=) |
| CA (1) | CA3090373A1 (https=) |
| EA (1) | EA202091816A1 (https=) |
| IL (1) | IL276327B2 (https=) |
| MX (1) | MX2020008041A (https=) |
| SG (1) | SG11202006433PA (https=) |
| WO (1) | WO2019151539A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| US12258597B2 (en) | 2018-02-07 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3163283A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
| CN115427059A (zh) * | 2020-01-31 | 2022-12-02 | 达因疗法公司 | 抗转铁蛋白受体（tfr）抗体及其用途 |
| WO2021167107A1 (ja) | 2020-02-22 | 2021-08-26 | Ｊｃｒファーマ株式会社 | ヒトトランスフェリンレセプター結合ペプチド |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN117957240A (zh) | 2021-08-19 | 2024-04-30 | 肽梦想株式会社 | 人转铁蛋白受体结合肽 |
| WO2023027125A1 (ja) | 2021-08-24 | 2023-03-02 | ペプチドリーム株式会社 | ヒトトランスフェリンレセプター結合抗体－ペプチドコンジュゲート |
| WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| CA3242731A1 (en) * | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| TW202434613A (zh) | 2023-02-17 | 2024-09-01 | 日商肽夢想股份有限公司 | 人類運鐵蛋白受體結合肽 |
| IL326018A (en) * | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| WO2025256433A1 (zh) * | 2024-06-14 | 2025-12-18 | 四川大学华西医院 | 一种转铁蛋白受体1靶向性糖苷水解酶复合体的制备方法及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995011317A1 (en) | 1993-10-19 | 1995-04-27 | The Scripps Research Institute | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
| AUPN523995A0 (en) | 1995-09-05 | 1995-09-28 | Crc For Biopharmaceutical Research Pty Ltd | Method for producing phage display vectors |
| EP1877099B1 (en) * | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| CN103201382A (zh) | 2010-11-08 | 2013-07-10 | 日本化学研究株式会社 | 新表达载体 |
| JP5957085B2 (ja) * | 2012-02-07 | 2016-07-27 | Ｊｃｒファーマ株式会社 | 改善されたバイオアベイラビリティーのためにａｔｆと融合させた薬剤 |
| AU2014218854B2 (en) * | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| EP3594240B1 (en) * | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| DK3386534T3 (da) * | 2015-12-08 | 2020-11-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| SG11201901495YA (en) * | 2016-08-25 | 2019-03-28 | Jcr Pharmaceuticals Co Ltd | Method for producing antibody fusion protein |
-
2019
- 2019-02-05 IL IL276327A patent/IL276327B2/en unknown
- 2019-02-05 US US16/963,956 patent/US20210038739A1/en not_active Abandoned
- 2019-02-05 SG SG11202006433PA patent/SG11202006433PA/en unknown
- 2019-02-05 EA EA202091816A patent/EA202091816A1/ru unknown
- 2019-02-05 CN CN201980011522.2A patent/CN111683972A/zh active Pending
- 2019-02-05 MX MX2020008041A patent/MX2020008041A/es unknown
- 2019-02-05 CA CA3090373A patent/CA3090373A1/en active Pending
- 2019-02-05 KR KR1020207024561A patent/KR20200116952A/ko not_active Ceased
- 2019-02-05 AU AU2019215782A patent/AU2019215782A1/en not_active Abandoned
- 2019-02-05 JP JP2019019212A patent/JP2019137675A/ja active Pending
- 2019-02-05 WO PCT/JP2019/004123 patent/WO2019151539A1/ja not_active Ceased
- 2019-02-05 EP EP19747769.8A patent/EP3750921A4/en active Pending
- 2019-02-05 BR BR112020013305-1A patent/BR112020013305A2/pt unknown
-
2023
- 2023-09-19 JP JP2023150649A patent/JP7591340B2/ja active Active
-
2024
- 2024-03-08 US US18/599,591 patent/US20240245797A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019137675A5 (https=) | ||
| JP7411316B2 (ja) | 三重特異性結合タンパク質と使用方法 | |
| TWI614264B (zh) | 含胜肽核的多臂接合物及其應用 | |
| TWI617319B (zh) | 用以治療病理性血栓的融合蛋白 | |
| TWI591075B (zh) | 含胜肽核的多臂接合物 | |
| JPH05502039A (ja) | 多価抗原結合性蛋白質 | |
| US20230118983A1 (en) | Tetravalent FZD and WNT Co-receptor Binding Molecules and Uses Thereof | |
| JP2022081634A (ja) | プロテアーゼで切断可能なリンカーを有するペプチド構築体 | |
| WO2018237338A1 (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| JP2008521426A5 (https=) | ||
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| CN1381461A (zh) | 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用 | |
| KR102444797B1 (ko) | α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도 | |
| US20240270797A1 (en) | Coronavirus neutralizing compositions and associated methods | |
| CN120590542A (zh) | 基于clec9a的嵌合蛋白复合物 | |
| WO2019192493A1 (zh) | 抗人lag-3单克隆抗体及其应用 | |
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 | |
| JP2022513626A5 (https=) | ||
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| JP2024527571A (ja) | インターロイキン－１アルファキメラタンパク質 | |
| NZ794344B2 (en) | TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN | |
| NZ794344A (en) | Tgfβr2 extracellular domain truncated molecule, fusion protein of tgfβr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein | |
| WO2024140919A1 (zh) | 抗crtam/抗pd-l1抗体及其应用 | |
| CA3238965A1 (en) | B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins | |
| JP2024533485A5 (https=) |